Patents by Inventor Vaclav Vetvicka

Vaclav Vetvicka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Systems and methods for diagnosis and prognosis of cancer
    Patent number: 8852870
    Abstract: Methods for diagnosing a cancer in a subject are provided that include determining an amount of autoantibodies immunoreactive to procathepsin D (pCD) in a sample obtained from the subject. Further provided are systems for diagnosing a cancer in a subject that include an autoantibody immunoreactive pCD antigen and a means for detecting binding of an autoantibody to the antigen.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: October 7, 2014
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Vaclav Vetvicka, Martin Fusek, Jarmila Zidkova
  • SYSTEMS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER
    Publication number: 20110081669
    Abstract: Methods for diagnosing a cancer in a subject are provided that include determining an amount of autoantibodies immunoreactive to procathepsin D (pCD) in a sample obtained from the subject. Further provided are systems for diagnosing a cancer in a subject that include an autoantibody immunoreactive pCD antigen and a means for detecting binding of an autoantibody to the antigen.
    Type: Application
    Filed: June 16, 2009
    Publication date: April 7, 2011
    Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: Vaclav Vetvicka, Martin Fusek, Jarmila Zidkova
  • Chemotherapeutic antineoplastic treatment
    Patent number: 7671040
    Abstract: Chemotherapeutic antineoplastic method comprising administration of an effective amount of an antineoplastic agent in conjunction with an effective amount of a ?-1,3 glucan.
    Type: Grant
    Filed: September 23, 2003
    Date of Patent: March 2, 2010
    Assignee: Laboratoires Goemar S.A.
    Inventors: Jean-Claude Yvin, Vaclav Vetvicka
  • Therapeutical combination against cancer
    Patent number: 7070778
    Abstract: The present invention relates to compositions and methods for treating humans and warm-blood animals suffering from cancer. More particularly, a therapeutical treatment in which a monoclonal antibody is administered with either ?-(1,3)-glucan like laminarin or a oligo-?-(1,3)-glucan and a pharmaceutically acceptable carrier, to patients suffering from cancer are described.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: July 4, 2006
    Assignee: Laboratoire Goemar SA
    Inventors: Jean-Claude Yvin, Edouard Panak, Vaclav Vetvicka
  • Therapeutical combination against cancer
    Publication number: 20050095250
    Abstract: The present invention relates to compositions and methods for treating humans and warm-blood animals suffering from cancer. More particularly, a therapeutical treatment in which a monoclonal antibody is administered with either ?-(1,3)-glucan like laminarin or a oligo-?-(1,3)-glucan and a pharmaceutically acceptable carrier, to patients suffering from cancer are described.
    Type: Application
    Filed: October 30, 2003
    Publication date: May 5, 2005
    Inventors: Jean-Claude Yvin, Edouard Panak, Vaclav Vetvicka
  • Chemotherapeutic antineoplastic treatment
    Publication number: 20050065111
    Abstract: Chemotherapeutic antineoplastic method comprising administration of an effective amount of an antineoplastic agent in conjunction with an effective amount of a ?-1,3 glucan.
    Type: Application
    Filed: September 23, 2003
    Publication date: March 24, 2005
    Inventors: Jean-Claude Yvin, Vaclav Vetvicka
  • Therapeutical treatment with oligo-beta- (1,3) -glucans, drugs used in said treatment
    Publication number: 20050065114
    Abstract: A therapeutical method comprising administration of a composition comprising an amount of oligo-?-(1,3)-glucan and a pharmaceutically acceptable carrier, to a human being or to a warm-blood animal suffering from a disease selected from the group consisting in a tumor, a cancer, a viral disease, a bacterial disease, a fungal disease, a disease of the immune system, an auto-immune disease or a disease related to a deficiency of immunostimulation, wherein the amount of oligo-?-(1,3)-glucan is effective to treat the disease.
    Type: Application
    Filed: September 23, 2003
    Publication date: March 24, 2005
    Inventors: Jean-Claude Yvin, Frank Jamois, Vaclav Vetvicka
  • Therapeutical treatments
    Patent number: 6660722
    Abstract: Therapeutical method comprising administration to a patient of an effective amount of especially soluble laminarin for the treatment of tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers, and for the treatment of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: December 9, 2003
    Assignee: Laboratoires Goemar S.A.
    Inventors: Jean-Claude Yvin, Vaclav Vetvicka
  • Therapeutical treatments
    Publication number: 20030119780
    Abstract: Therapeutical method comprising administration to a patient of an effective amount of especially soluble laminarin for the treatment of tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers, and for the treatment of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals.
    Type: Application
    Filed: November 30, 2001
    Publication date: June 26, 2003
    Inventors: Jean-Claude Yvin, Vaclav Vetvicka
  • Method for inhibition of breast tumor growth
    Patent number: 5800814
    Abstract: Human procathepsin D was demonstrated to be mitogenic for breast cancer cells but not normal cells. The activation peptide of the procathepsin D appears to be responsible, since inhibition of enhancement of proliferation of breast cancer cells can be obtained by inhibition of the activation peptide through the use of an agent such as an antibody immunoreactive with the activation peptide.
    Type: Grant
    Filed: April 22, 1994
    Date of Patent: September 1, 1998
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Martin Fusek, Vaclav Vetvicka